1. Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2023 Subject(s): Ethnic and Racial Minorities -- statistics & numerical dataGovernment RegulationHealth InequitiesHealthcare DisparitiesMedicaidMorphinans -- supply & distributionOpiate Substitution TreatmentOpioid-Related Disorders -- drug therapyUnited States
2. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022 Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023 Subject(s): BuprenorphineDrug Users -- statistics & numerical dataGovernment RegulationMedicare Part D -- economicsOpiate Substitution TreatmentOpioid-Related Disorders -- drug therapyPrescription Drug Diversion -- statistics & numerical dataUnited States
3. The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2023 Subject(s): Government RegulationMedicareOpiate Overdose -- prevention & controlOpiate Substitution TreatmentOpioid-Related Disorders -- drug therapyUnited States
